Drugs / berobenatide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07595549 | Jun 2026 → May 2028 expected | obesity disorder | Pfizer | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-06 | Pfizer | Results Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide pfizer.com ↗
Pfizer Inc. (NYSE: PFE) today presented detailed results from multiple Phase 2b studies of berobenatide (PF’3944), an investigational, potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, during a late-breaking expert symposium at the 86 th Scientific Sessions of the American Diabetes Association (ADA). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-06 | Pfizer | Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide pfizer.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | berobenatide | “The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944).” NCT07595549 ↗ |
| Known as | PF-08653944 | “The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944).” NCT07595549 ↗ |
| Route | Subcutaneous | “By Subcutaneous Injection” NCT07595549 ↗ |